For decades, China has had the largest population in the world. However, recent demographic trends have resulted in India being the world’s most populous country. COVID-19, an aging population and low birth rate have all contributed to the decrease in China’s population growth, but what does this really mean to the pharmaceutical industry?
Watch this webcast, in which our in-house experts, Wan Ling Neo and Callum McCulloch, explain the impact of the demographic shift, and the new policies that have been introduced. They provide an in-depth understanding of the pharma landscape in China which offers exciting potential, such as the breakthrough of biosimilars, the vaccination boom and Healthy China 2030 policy. The presenters further showcase where to play and how to win, providing examples spanning from market access to clinical trial design and patient journey research.
What are the key takeaways?
Jump to a slide with the slide dots.
In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma.
Read moreOur client wanted to understand decision making in allergy diagnostics and perceptions of allergy testing platforms.
Read moreDid you know that we have conducted over 200 market research projects in China? In this infographic we reveal our top 10 tips and important things.
Read moreRapport is our monthly newsletter where we share our latest expertise and experience.